Accepted answer
Twenty-one days at minus 20 °C. minus 20 °C is 25 kelvin below a refrigerator, and below the glass transition of a lyophilised cake the ten-degree rule of thumb stops applying at all — solid-state chemistry is not slow liquid chemistry, it is a different regime, and the failure modes that survive it are mechanical rather than chemical. The thing to establish is how many times it froze and thawed, not how long it sat: twenty-one days at one stable temperature is gentler than a single uncontrolled transition. Either way, record the twenty-one days and the temperature now, while you still know them; an excursion you did not write down is an excursion you cannot interpret later.
Answering this needs the transit duration and the ambient temperature, and then the arithmetic is straightforward.
That is the argument for shipping lyophilised rather than for shipping colder. A dry powder with low residual moisture is stable at ambient for months; the pathways that matter need water.
Reported and extrapolated stability by condition
| State | Condition | Usable window | Basis |
|---|
| Lyophilised solid | −20 °C, sealed, dry | 24–36 months | Supplier guidance |
| Lyophilised solid | 2–8 °C, sealed | 12–24 months | Supplier guidance |
| Lyophilised solid | 25 °C, sealed | 4–8 weeks | Extrapolated (Arrhenius) |
| Lyophilised solid | 40 °C, sealed | 1–2 weeks | Extrapolated |
| Solution, preserved | 2–8 °C | 28 days | USP microbiological convention |
| Solution, preserved | 25 °C | 3–7 days | Extrapolated |
| Solution, unpreserved | 2–8 °C | 24 hours | USP microbiological convention |
Windows for the solid state are chemical; windows for solution are microbiological and usually shorter than the chemical limit.
Arrhenius behaviour means the degradation rate roughly doubles per ten degrees. A week at thirty degrees is therefore a meaningful exposure for a solution and an immaterial one for a dry solid.
Arrhenius kinetics predict approximately a doubling of degradation rate per ten-degree rise and are the standard basis for cold-chain design.
Nothing here is medical advice, and research-use compounds are not approved for human use.
A liquefied pack is expected. It is not evidence of a problem.